person · Reporting owner
Capone Mark Christopher
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DermTech, Inc.DMTK · Entity 89998 | Director | June 01, 2023 | June 05, 2023 |
| MESA LABORATORIES INC /CO/MLAB · Entity 5221 | Director | September 09, 2026 | September 11, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | President & C.E.O. | September 30, 2019 | October 01, 2019 |
| SERA PROGNOSTICS, INC.SERA · Entity 304 | Director | July 10, 2026 | July 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DermTech, Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,054 |
Reported balance
After 2023-06-01 transaction · row 1
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 82,054 F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.
MESA LABORATORIES INC /CO/
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units - 4SEC Table II · derivative / convertible security | Direct | 2,423 |
Reported balance
After 2026-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-09 · Grant · Acquired 2,423 · Balance 2,423 F1: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock F2: RSUs that vest on September 9, 2027 F3: Not Applicable |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock
F2: RSUs that vest on September 9, 2027
F3: Not Applicable
MYRIAD GENETICS INC
Report date September 30, 2019 · Filed October 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 522,216 |
Ending reported balance
After 2019-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-09-30 · Disposition to issuer · Disposed 8,727 · Balance 540,511 F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Row 2 · 2019-09-30 · Disposition to issuer · Disposed 18,295 · Balance 522,216 F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person.
SERA PROGNOSTICS, INC.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 44,379 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Grant · Acquired 42,404 · Balance 42,404 F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest in three annual installments beginning with July 10, 2027, subject to the Reporting Person continuing to provide services to the issuer. Row 2 · 2026-07-10 · Grant · Acquired 1,975 · Balance 44,379 F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 62,766 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Grant · Acquired 62,766 · Balance 62,766 F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the grant date, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 3,037 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Grant · Acquired 3,037 · Balance 3,037 F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest in three annual installments beginning with July 10, 2027, subject to the Reporting Person continuing to provide services to the issuer.
F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the grant date, subject to the Reporting Person continuing to provide services to the issuer.
F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 18:13 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | GrantRestricted Stock Units - 4 · Derivative | 2,423 | $0.00 | $0.00 |
DisclosureSEC source: 0000724004-26-000097 · primary_doc.xml · derivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,423 Underlying: Common Stock · 2,423 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock F2 · derivative.exercise_date: RSUs that vest on September 9, 2027 F3 · derivative.expiration_date: Not Applicable Read SEC document |
| August 15, 2026 Filed Aug 17, 2026 23:40 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionRestricted Stock Units - 3 · Derivative | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0000724004-26-000091 · primary_doc.xml · derivative · entry 2 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,784 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: RSUs that vested on August 15, 2026 F3 · derivative.expiration_date: Not Applicable Read SEC document |
| August 15, 2026 Filed Aug 17, 2026 23:40 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0000724004-26-000091 · primary_doc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 3,037 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001352413-26-000004 · ownership.xml · derivative · entry 4 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,037 Underlying: Class A Common Stock · 3,037 shares Expires 2036-07-10 F4 · derivative.exercise_date: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 62,766 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001352413-26-000004 · ownership.xml · derivative · entry 3 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,766 Underlying: Class A Common Stock · 62,766 shares Expires 2036-07-10 F3 · derivative.exercise_date: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the grant date, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 1,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001352413-26-000004 · ownership.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,379 F2 · shares: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 42,404 | $0.00 | $0.00 |
DisclosureSEC source: 0001352413-26-000004 · ownership.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,404 F1 · shares: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest in three annual installments beginning with July 10, 2027, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| March 10, 2026 Filed Mar 10, 2026 19:46 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | PurchaseCommon Stock | 1,301 | $76.35 | $99,331.35 |
DisclosureSEC source: 0000724004-26-000022 · primary_doc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,429 Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 17:45 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | GrantRestricted Stock Units - 3 · Derivative | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001197710-25-000004 · primary_doc.xml · derivative · entry 3 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,784 Underlying: Common Stock · 2,784 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive on share of the Issuer's common stock F4 · derivative.exercise_date: RSUs that vest on August 15, 2026 F3 · derivative.expiration_date: Not Applicable Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 17:45 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionRestricted Stock Units - 2 · Derivative | 1,404 | $0.00 | $0.00 |
DisclosureSEC source: 0001197710-25-000004 · primary_doc.xml · derivative · entry 2 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,404 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive on share of the Issuer's common stock F2 · derivative.exercise_date: RSUs that vested on August 15, 2025 F3 · derivative.expiration_date: Not Applicable Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 17:45 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionCommon Stock | 1,404 | $0.00 | $0.00 |
DisclosureSEC source: 0001197710-25-000004 · primary_doc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 15:08 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | GrantRestricted Stock Units - 2 · Derivative | 1,404 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-24-000014 · primary_doc.xml · derivative · entry 3 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,404 Underlying: Common Stock · 1,404 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock F4 · derivative.exercise_date: RSUs that vest on August 15, 2025 F3 · derivative.expiration_date: Not Applicable Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 15:08 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionRestricted Stock Units - 1 · Derivative | 724 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-24-000014 · primary_doc.xml · derivative · entry 2 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: RSUs that vest on August 15, 2024 F3 · derivative.expiration_date: Not Applicable Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 15:08 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionCommon Stock | 724 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-24-000014 · primary_doc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 18:10 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | GrantRestricted Stock Units -1 · Derivative | 724 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-24-000002 · primary_doc.xml · derivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724 Underlying: Common Stock · 724 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: RSUs that vest on August 15, 2024 F3 · derivative.expiration_date: Not Applicable Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:22 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 35,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034585 · doc4.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,054 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024. Read SEC document |
| July 18, 2022 Filed Jul 21, 2022 00:12 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 19,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042798 · doc4.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,340 F2 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in one installment on May 26, 2023. Read SEC document |
| July 18, 2022 Filed Jul 21, 2022 00:12 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 26,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042798 · doc4.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,480 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in three equal annual installments over the three-year period following the grant date, subject to the reporting person's continued service. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 22:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 18,295 | $28.63 | $523,785.85 |
DisclosureSEC source: 0001352413-19-000006 · edgardoc.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,216 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 22:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 8,727 | $28.63 | $249,854.01 |
DisclosureSEC source: 0001352413-19-000006 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,511 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 21:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 18,295 | $29.93 | $547,569.35 |
DisclosureSEC source: 0001352413-19-000004 · edgardoc.xml · nonDerivative · entry 3 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,238 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 21:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 15,800 | $29.93 | $472,894.00 |
DisclosureSEC source: 0001352413-19-000004 · edgardoc.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,533 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 21:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 142,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001352413-19-000004 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,333 F1 · kind: Consists of performance stock units granted pursuant to the Companys 2017 Employee, Director and Consultant Equity Incentive Plan. Performance stock units initially granted on September 19, 2018, subject to accomplishment of pre-determined financial performance requirements. On September 25, 2019, the Compensation Committee determined the final award amount based on the accomplishment of the applicable financial performance requirements. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 25, 2019, 25% on September 25, 2020, 25% on September 25, 2021, and 25% on September 25, 2022. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 58,138 | $0.00 Strike: $30.34 | $0.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · derivative · entry 12 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,138 shares Expires 2019-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 70,672 | $0.00 Strike: $23.11 | $0.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · derivative · entry 11 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,672 shares Expires 2020-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,862 | $0.00 Strike: $30.34 | $0.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · derivative · entry 10 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,862 shares Expires 2019-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,328 | $0.00 Strike: $23.11 | $0.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · derivative · entry 9 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,328 shares Expires 2020-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,862 | $44.00 | $169,928.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 8 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,833 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 3,862 | $30.34 | $117,173.08 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 7 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 58,138 | $44.00 | $2,558,072.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 6 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,833 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 58,138 | $30.34 | $1,763,906.92 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 5 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 4,328 | $44.00 | $190,432.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 4 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,833 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 4,328 | $23.11 | $100,020.08 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 3 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 70,672 | $44.00 | $3,109,568.00 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,833 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 70,672 | $23.11 | $1,633,229.92 |
DisclosureSEC source: 0001352413-19-000002 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 12:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 8,727 | $46.00 | $401,442.00 |
DisclosureSEC source: 0001352413-18-000012 · edgardoc.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,833 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 12:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 18,295 | $46.00 | $841,570.00 |
DisclosureSEC source: 0001352413-18-000012 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,560 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 18:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 18,295 | $46.65 | $853,461.75 |
DisclosureSEC source: 0001352413-18-000010 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,855 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 16:02 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001352413-18-000008 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,150 F1 · kind: Consists of performance stock units granted pursuant to the Companys 2010 Employee, Director and Consultant Equity Incentive Plan. Performance stock units initially granted on September 17, 2017, subject to accomplishment of pre-determined financial performance requirements. On September 19, 2018, the Compensation Committee determined the final award amount based on the accomplishment of the applicable financial performance requirements. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 25, 2018, 25% on September 25, 2019, 25% on September 25, 2020, and 25% on September 25, 2021. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 11,025 | $46.35 | $511,008.75 |
DisclosureSEC source: 0001352413-18-000006 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,150 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 77,654 | $0.00 Strike: $30.12 | $0.00 |
DisclosureSEC source: 0001352413-18-000004 · edgardoc.xml · derivative · entry 6 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,654 shares Expires 2019-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,346 | $0.00 Strike: $30.12 | $0.00 |
DisclosureSEC source: 0001352413-18-000004 · edgardoc.xml · derivative · entry 5 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,346 shares Expires 2019-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 2,346 | $41.00 | $96,186.00 |
DisclosureSEC source: 0001352413-18-000004 · edgardoc.xml · nonDerivative · entry 4 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,175 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 2,346 | $30.12 | $70,661.52 |
DisclosureSEC source: 0001352413-18-000004 · edgardoc.xml · nonDerivative · entry 3 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 77,654 | $41.00 | $3,183,814.00 |
DisclosureSEC source: 0001352413-18-000004 · edgardoc.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,175 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 77,654 | $30.12 | $2,338,938.48 |
DisclosureSEC source: 0001352413-18-000004 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0000899243-18-014717 · doc4.xml · derivative · entry 3 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2018-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 90,000 | $38.00 | $3,420,000.00 |
DisclosureSEC source: 0000899243-18-014717 · doc4.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,175 Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 90,000 | $22.93 | $2,063,700.00 |
DisclosureSEC source: 0000899243-18-014717 · doc4.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 9,238 | $36.18 | $334,230.84 |
DisclosureSEC source: 0001352413-17-000006 · edgardoc.xml · nonDerivative · entry 2 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,175 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.